Skip to content
IP + Technology Law
Home  »  News & Insights  »  Publications

Lessons From The 1st Biopharma Inter Partes Reviews | Law360

April 16, 2015  | Eli A. Loots, Ph.D.

Recently, the Patent Trial and Appeal Board issued its first set of final written decisions in three inter partes reviews relating to molecules in the large molecule biopharma space (IPR2013-00534, IPR2013- 00535 and IPR2013-00537). Biosimilar companies will no doubt be looking to these decisions as a roadmap for clearing patent landscapes for their own biosimilar products in the coming years. Read more below or download the PDF.

Lessons From The 1st Biopharma Inter Partes Reviews from Knobbe Martens Olson & Bear

Related Links

Practice Areas

Industries

News & Insights

News
Jun 2026
Jarom Kesler Comments on USPTO Ex Parte Reexamination Denial Trends in Law360
In the Law360 article “USPTO Clamping Down Reexam Bids After IPR Denials,” Knobbe Martens partner Jarom Kesler shared how a recent ruling from the U.S. Patent and Trademark Office (USPTO)...
Publications
Jun 2026
What the USPTO’s New 30-Day Director Review Deadline for Decisions Instituting Trial Means for PTAB Petitioners and Patent Owners
Key Takeaway: In a precedential decision in Light & Wonder, Inc. v. Evolution Malta Ltd., U.S. Patent and Trademark Office Director Squires extended the deadline for requesting Director Review of...
Publications
Jul 2026
Jeremiah Helm and Sean Murray Analyze Federal Circuit Ruling on “About” and Patent Claim Indefiniteness in Law360
In their latest Law360 column on recent notable Federal Circuit decisions, Knobbe Martens partners Jeremiah Helm and Sean Murray analyze the Federal Circuit’s decision in Enviro Tech Chemical Services, Inc....